BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Avelumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Avelumab\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03815643-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Avelumab: Phase 3 readout est. (NCT03815643)
DESCRIPTION:Avelumab\, phase 3.\nStudy: Avelumab Program Rollover Study\nEs
 timated primary completion: 24 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03815643
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05222932-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 1 readout est. (NCT05222932)
DESCRIPTION:Avelumab\, phase 1.\nStudy: Oncolytic Adenovirus TILT-123 and A
 velumab for Treatment of Solid Tumors Refractory to or Progressing After A
 nti-PD(L)1\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05222932
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04261855-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT04261855)
DESCRIPTION:Avelumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: Targeted 
 Therapy and Avelumab in Merkel Cell Carcinoma\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ave
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04261855
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03573648-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Avelumab: Phase 2 readout est. (NCT03573648)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Neoadjuvant Endocrine Therapy\, Pal
 bociclib\, Avelumab in Estrogen Receptor Positive Breast Cancer\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03573648
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391479-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 2 readout est. (NCT03391479)
DESCRIPTION:Avelumab\, phase 2.\nStudy: A Study of Avelumab in Penile Cance
 r Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03391479
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Avelumab\, phase 3\, Urothelial Carcinoma.\nStudy: Continued Ac
 cess Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab 
 Parent Studies That Are Closing\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03971409-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Avelumab: Phase 2 readout est. (NCT03971409)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Avelumab With Binimetinib\, Sacituz
 umab Govitecan\, or Liposomal Doxorubicin in Treating Stage IV or Unresect
 able\, Recurrent Triple Negative Breast Cancer\nEstimated primary completi
 on: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03971409
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03744793-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Avelumab: Phase 2 readout est. (NCT03744793)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pemetrexed a
 nd Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial
  Cancer\nEstimated primary completion: 31 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03744793
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Study of AU-007\, A Monoclonal An
 tibody That Binds to IL-2 and Inhibits IL-2Rα Binding\, in Patients With 
 Unresectable Locally Advanced or Metastatic Cancer\nEstimated primary comp
 letion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05267626
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04792073-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Avelumab: Phase 2 readout est. (NCT04792073)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Study of Av
 elumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcin
 oma\nEstimated primary completion: March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04792073
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03076554-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Avelumab: Phase 2 readout est. (NCT03076554)
DESCRIPTION:Avelumab\, phase 2.\nStudy: A Pilot Study to Investigate the Sa
 fety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic
  Carcinoma After Progression on Platinum-Based Chemotherapy\nEstimated pri
 mary completion: 30 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/avelumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03076554
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Avelumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Avelumab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1/PD
 -L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEstim
 ated primary completion: 31 March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03964532-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT03964532)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: TALAVE: Induction Talazoparib Fol
 lowed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
 \nEstimated primary completion: April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03964532
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707808-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT03707808)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Intratumoral Injection of Autolog
 ous CD1c (BDCA-1)+ myDC\, AS01B\, and Ipilimumab Plus Systemic Nivolumab\n
 Estimated primary completion: 23 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03707808
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04071236-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT04071236)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Radiation Medication (Radium-223 
 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medicati
 on (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type o
 f Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal T
 herapy\nEstimated primary completion: 30 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04071236
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892860-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Avelumab: Phase 2 readout est. (NCT06892860)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Comparing 3 
 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab i
 n Advanced Urothelial Cancer\nEstimated primary completion: 30 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06892860
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841148-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Avelumab: Phase 2 readout est. (NCT04841148)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Avelumab or Hydroxychloroquine With
  or Without Palbociclib to Eliminate Dormant Breast Cancer\nEstimated prim
 ary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04841148
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068194-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT04068194)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Testing the Combination of New An
 ti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced
 /Metastatic Solid Tumors and Hepatobiliary Malignancies\nEstimated primary
  completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04068194
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04360941-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Avelumab: Phase 1 readout est. (NCT04360941)
DESCRIPTION:Avelumab\, phase 1.\nStudy: PAveMenT: Palbociclib and Avelumab 
 in Metastatic AR+ Triple Negative Breast Cancer\nEstimated primary complet
 ion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/av
 elumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04360941
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869473-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Avelumab: Phase 2 readout est. (NCT06869473)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Cetuximab Plus Platinum and Taxane-
 based Chemotherapy\, Followed by Avelumab and Cetuximab\, as First-line Tr
 eatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HN
 SCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.\nEstima
 ted primary completion: 20 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06869473
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518564-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Avelumab: Phase 2 readout est. (NCT06518564)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Avelumab and M1774 in ARID1A-mutate
 d Endometrial Cancer\nEstimated primary completion: 31 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06518564
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228066-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Avelumab: Phase 2 readout est. (NCT06228066)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Lurbinectedin With or Without Avelu
 mab in Small Cell Carcinoma of the Bladder (LASER)\nEstimated primary comp
 letion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06228066
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640725-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20271002
DTEND;VALUE=DATE:20271003
SUMMARY:Avelumab: Phase 2 readout est. (NCT06640725)
DESCRIPTION:Avelumab\, phase 2.\nStudy: Study of TPEx Followed by a Mainten
 ance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squ
 amous Cell Carcinoma of the H&N\nEstimated primary completion: 2 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06640725
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02767063-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT02767063)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Therapies in Combination or Seque
 ntially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic My
 elogenous Leukemia Patients in CCR (ACTIW)\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/avelum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 2767063
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02999087-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avelumab: Phase 3 readout est. (NCT02999087)
DESCRIPTION:Avelumab\, phase 3.\nStudy: Randomized Trial of Avelumab-cetuxi
 mab-radiotherapy Versus SOCs in LA SCCHN (REACH)\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02999087
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947500-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Avelumab: Phase 2 readout est. (NCT05947500)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Testing the
  Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Ev
 aluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer\
 , MATRiX Trial\nEstimated primary completion: 1 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05947500
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Avelumab: Phase 1 readout est. (NCT06204614)
DESCRIPTION:Avelumab\, phase 1\, Urothelial Carcinoma.\nStudy: Drug Screeni
 ng Using IMD in Bladder Cancer\nEstimated primary completion: 1 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06204614
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05102721-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT05102721)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: Trial of Immunotherapy With Avelu
 mab and Pepinemab As Second Line For Patients With Metastatic Pancreatic A
 denocarcinoma\nEstimated primary completion: 31 December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05102721
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03271372-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Avelumab: Phase 3 readout est. (NCT03271372)
DESCRIPTION:Avelumab\, phase 3\, Merkel Cell Carcinoma.\nStudy: Adjuvant Av
 elumab in Merkel Cell Cancer\nEstimated primary completion: 31 January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03271372
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Avelumab: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Avelumab\, phase 2.\nStudy: ProTarget - A Danish Nationwide Cli
 nical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEstim
 ated primary completion: 30 April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110038-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Avelumab: Phase 2 readout est. (NCT07110038)
DESCRIPTION:Avelumab\, phase 2.\nStudy: DEPECA-1 - A Phase II Study to Eval
 uate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab f
 or Advanced and Metastatic Penile Carcinoma\nEstimated primary completion:
  May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07110
 038
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092958-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Avelumab: Phase 3 readout est. (NCT05092958)
DESCRIPTION:Avelumab\, phase 3\, Urothelial Carcinoma.\nStudy: Testing the 
 Addition of the Anti-cancer Drug\, Cabozantinib\, to the Usual Immunothera
 py Treatment\, Avelumab\, in Patients With Metastatic Urothelial Cancer\, 
 MAIN-CAV Study\nEstimated primary completion: 15 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05092958
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Avelumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: QUILT-3.055
 : A Study of Combination Immunotherapies in Patients Who Have Previously R
 eceived Treatment With Immune Checkpoint Inhibitors\nEstimated primary com
 pletion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03228667
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Avelumab: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study of Sac
 ituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be R
 emoved or Has Spread\nEstimated primary completion: April 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03547973
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2017@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Avelumab\, phase 1/2.\nStudy: European Proof-of-Concept Therape
 utic Stratification Trial of Molecular Anomalies in Relapsed or Refractory
  Tumors\nEstimated primary completion: February 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
